2nd drug approved with Lycalis' support

Image for 2nd drug approved with Lycalis' support

Joint-ACTRIMS-ECTRIMS Paris 2017: Dr Wolf in front of a siponimod poster co-authored by himself.

2nd drug approved with Lycalis' support

27 Mar 2019  |  News  |  Press Releases

Yesterday, the US FDA approved Novartis' drug Mayzent® (siponimod) for treatment of relapsing forms of multiple sclerosis (RMS) including clinically isolated syndrome (CIS), relapsing remitting disease, and active secondary progressive disease, in adults. Lycalis has accompanied the development of siponimod since 2009.

The FDA's approval is based on the Phase III EXPAND trial demonstrating that Mayzent® significantly reduced the risk of MS disease progression. Mayzent® is a next-generation, selective sphingosine 1-phosphate (S1P) receptor modulator.

After Synthon's follow-on glatiramer acetate, Mayzent® is the second approved drug developed with Dr. Wolf's support.

Novartis press release

US FDA press release

Mayzent label